The ErbB/HER family of protein-tyrosine kinases and cancer
R Roskoski Jr - Pharmacological research, 2014 - Elsevier
The human epidermal growth factor receptor (EGFR) family consists of four members that
belong to the ErbB lineage of proteins (ErbB1–4). These receptors consist of a glycosylated …
belong to the ErbB lineage of proteins (ErbB1–4). These receptors consist of a glycosylated …
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics
CL Arteaga, JA Engelman - Cancer cell, 2014 - cell.com
ERBB receptors were linked to human cancer pathogenesis approximately three decades
ago. Biomedical investigators have since developed substantial understanding of the …
ago. Biomedical investigators have since developed substantial understanding of the …
Antitumour immunity regulated by aberrant ERBB family signalling
S Kumagai, S Koyama, H Nishikawa - Nature Reviews Cancer, 2021 - nature.com
Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
R Roskoski Jr - Pharmacological research, 2019 - Elsevier
The EGFR family is among the most investigated receptor protein-tyrosine kinase groups
owing to its general role in signal transduction and in oncogenesis. This family consists of …
owing to its general role in signal transduction and in oncogenesis. This family consists of …
Perturbation-response genes reveal signaling footprints in cancer gene expression
Aberrant cell signaling can cause cancer and other diseases and is a focal point of drug
research. A common approach is to infer signaling activity of pathways from gene …
research. A common approach is to infer signaling activity of pathways from gene …
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
The HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) is approved
for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and …
for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and …
Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy
A Plückthun - Annual review of pharmacology and toxicology, 2015 - annualreviews.org
Designed ankyrin repeat proteins (DARPins) can recognize targets with specificities and
affinities that equal or surpass those of antibodies, but because of their robustness and …
affinities that equal or surpass those of antibodies, but because of their robustness and …
Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models
A Kulukian, P Lee, J Taylor, R Rosler, P de Vries… - Molecular Cancer …, 2020 - AACR
HER2 is a transmembrane tyrosine kinase receptor that mediates cell growth, differentiation,
and survival. HER2 is overexpressed in approximately 20% of breast cancers and in subsets …
and survival. HER2 is overexpressed in approximately 20% of breast cancers and in subsets …
Trastuzumab mechanism of action; 20 years of research to unravel a dilemma
Simple Summary Overexpression of HER2 receptors have been identified in various types of
cancer including breast cancer and ovarian cancer. HER2 overexpression is generally …
cancer including breast cancer and ovarian cancer. HER2 overexpression is generally …
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
C Vernieri, M Milano, M Brambilla, A Mennitto… - Critical reviews in …, 2019 - Elsevier
HER2-positive breast cancer (HER2+ BC) represents 15–20% of all BCs. In the last two
decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors …
decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors …